Compare ASTRAZENECA PHARMA with STRIDES PHARMA SCIENCE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs STRIDES PHARMA SCIENCE - Comparison Results

ASTRAZENECA PHARMA     Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

STRIDES PHARMA SCIENCE 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA STRIDES PHARMA SCIENCE ASTRAZENECA PHARMA/
STRIDES PHARMA SCIENCE
 
P/E (TTM) x 114.4 45.2 253.1% View Chart
P/BV x 35.0 2.1 1,659.6% View Chart
Dividend Yield % 0.0 0.2 -  

Financials

 ASTRAZENECA PHARMA   STRIDES PHARMA SCIENCE
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-18
STRIDES PHARMA SCIENCE
Mar-18
ASTRAZENECA PHARMA/
STRIDES PHARMA SCIENCE
5-Yr Chart
Click to enlarge
High Rs1,2781,147 111.4%   
Low Rs883642 137.5%   
Sales per share (Unadj.) Rs228.4317.2 72.0%  
Earnings per share (Unadj.) Rs10.47.8 132.1%  
Cash flow per share (Unadj.) Rs16.325.1 64.9%  
Dividends per share (Unadj.) Rs02.00 0.0%  
Dividend yield (eoy) %00.2 0.0%  
Book value per share (Unadj.) Rs98.8274.3 36.0%  
Shares outstanding (eoy) m25.0089.50 27.9%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x4.72.8 167.8%   
Avg P/E ratio x104.2114.0 91.4%  
P/CF ratio (eoy) x66.435.7 186.1%  
Price / Book Value ratio x10.93.3 335.3%  
Dividend payout %025.5 0.0%   
Avg Mkt Cap Rs m27,00880,058 33.7%   
No. of employees `0001.42.5 54.1%   
Total wages/salary Rs m1,5354,341 35.4%   
Avg. sales/employee Rs Th4,210.911,325.8 37.2%   
Avg. wages/employee Rs Th1,132.21,731.4 65.4%   
Avg. net profit/employee Rs Th191.1280.1 68.2%   
INCOME DATA
Net Sales Rs m5,71028,394 20.1%  
Other income Rs m123941 13.0%   
Total revenues Rs m5,83329,334 19.9%   
Gross profit Rs m4633,965 11.7%  
Depreciation Rs m1471,540 9.6%   
Interest Rs m01,962 0.0%   
Profit before tax Rs m4381,403 31.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-168 0.0%   
Extraordinary Inc (Exp) Rs m0-436 0.0%   
Tax Rs m17997 183.9%   
Profit after tax Rs m259702 36.9%  
Gross profit margin %8.114.0 58.0%  
Effective tax rate %40.86.9 589.0%   
Net profit margin %4.52.5 183.5%  
BALANCE SHEET DATA
Current assets Rs m3,20924,836 12.9%   
Current liabilities Rs m2,07018,993 10.9%   
Net working cap to sales %20.020.6 97.0%  
Current ratio x1.61.3 118.6%  
Inventory Days Days7271 101.9%  
Debtors Days Days35113 30.8%  
Net fixed assets Rs m79034,289 2.3%   
Share capital Rs m50895 5.6%   
"Free" reserves Rs m2,41923,651 10.2%   
Net worth Rs m2,46924,546 10.1%   
Long term debt Rs m015,513 0.0%   
Total assets Rs m4,60565,437 7.0%  
Interest coverage xNM1.7-  
Debt to equity ratio x00.6 0.0%  
Sales to assets ratio x1.20.4 285.7%   
Return on assets %5.64.1 138.2%  
Return on equity %10.52.9 366.8%  
Return on capital %17.76.9 257.3%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m30015,697 1.9%   
Fx outflow Rs m2,015735 274.0%   
Net fx Rs m-1,71514,962 -11.5%   
CASH FLOW
From Operations Rs m881,871 4.7%  
From Investments Rs m-945,826 -1.6%  
From Financial Activity Rs mNA-10,157 0.0%  
Net Cashflow Rs m-6-2,615 0.2%  

Share Holding

Indian Promoters % 0.0 27.7 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 0.3 37.8 0.8%  
FIIs % 15.7 8.6 182.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 25.9 35.1%  
Shareholders   12,856 56,241 22.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   JUBILANT PHARMOVA   PANACEA BIOTECH  GLENMARK PHARMA  GSK PHARMA  FRESENIUS KABI ONCO.  

Compare ASTRAZENECA PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

A Time Correction in the Nifty(Momentum Moves)

The week belonged to the bulls after bears ended the party in February. March started with gains for the bulls but historically, March has been a bears' month.

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (3QFY21); Net Profit Down 21.2% (Quarterly Result Update)

Feb 11, 2021 | Updated on Feb 11, 2021

For the quarter ended December 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 211 m (down 21.2% YoY). Sales on the other hand came in at Rs 2 bn (down 10.5% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (3QFY21); Net Profit Down 46.4% (Quarterly Result Update)

Feb 5, 2021 | Updated on Feb 5, 2021

For the quarter ended December 2020, STRIDES PHARMA SCIENCE has posted a net profit of Rs 621 m (down 46.4% YoY). Sales on the other hand came in at Rs 8 bn (up 13.6% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY21); Net Profit Down 13.4% (Quarterly Result Update)

Sep 22, 2020 | Updated on Sep 22, 2020

For the quarter ended June 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 186 m (down 13.4% YoY). Sales on the other hand came in at Rs 2 bn (down 5.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY21); Net Profit Up 184.5% (Quarterly Result Update)

Aug 20, 2020 | Updated on Aug 20, 2020

For the quarter ended June 2020, STRIDES PHARMA SCIENCE has posted a net profit of Rs 1 bn (up 184.5% YoY). Sales on the other hand came in at Rs 8 bn (up 14.0% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY20); Net Profit Down 2.5% (Quarterly Result Update)

May 20, 2020 | Updated on May 20, 2020

For the quarter ended March 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 96 m (down 2.5% YoY). Sales on the other hand came in at Rs 2 bn (up 2.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps(Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Make Rs 5,000 Per Day Trading the Market(Fast Profits Daily)

Feb 25, 2021

In this video, I'll show you how to get started on the path to daily trading profits.

The Hidden Tesla in My Great Indian Wealth Project(Profit Hunter)

Feb 23, 2021

An Indian company founded three decades ago in a garage caught my attention...

Gold 65,000 and Silver 84,000 in 2022

Feb 26, 2021

In this episode of the Investor Hour, India's #1 trader, Vijay Bhambwani, talks to us about the stock market, his new targets for gold and silver, the best long-term investment opportunity, and a lot more.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Mar 5, 2021 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 5-YR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS